Skip to main content
Monday, November 16, 2026Nov 16

U.S. medical marketing reaches $30 billion, drug ads top surge

FILE - In this July 10, 2018 file photo, bottles of prescription medicines ride on a conveyor belt at a pharmacy warehouse in Florence, N.J. According to a report released on Tuesday, Jan. 8, 2018, annual spending by the U.S. health industry on ads and promotions has reached $30 billion. That includes advertisements for prescription drugs that were shown 5 million times on TV and elsewhere in 2016. That’s a huge increase in 20 years and just part of broad health industry efforts to promote drugs, devices, lab tests and even new hospitals. (AP Photo/Julio Cortez, File)
FILE - In this July 10, 2018 file photo, bottles of prescription medicines ride on a conveyor belt at a pharmacy warehouse in Florence, N.J. According to a report released on Tuesday, Jan. 8, 2018, annual spending by the U.S. health industry on ads and promotions has reached $30 billion. That includes advertisements for prescription drugs that were shown 5 million times on TV and elsewhere in 2016. That’s a huge increase in 20 years and just part of broad health industry efforts to promote drugs, devices, lab tests and even new hospitals. (AP Photo/Julio Cortez, File)

Ads for prescription drugs appeared 5 million times in just one year, capping a recent surge in U.S. medical marketing, a new analysis found.

The advertisements for various medicines showed up on TV, newspapers, online sites and elsewhere in 2016. Their numbers soared over 20 years as part of broad health industry efforts to promote drugs, devices, lab tests and even hospitals.

The researchers estimated that medical marketing reached $30 billion in 2016, up from $18 billion in 1997. Spending on consumer-focused ads climbed fastest. But marketing to doctors and other health professionals still grabbed the biggest share with the bulk of it paying for free drug samples.

“Marketing drives more treatments, more testing” that patients don’t always need, said Dr. Steven Woloshin, a Dartmouth College health policy expert. Woloshin wrote the report with his wife, Dr. Lisa Schwartz, both longtime critics of overdiagnosis and overtreatment. She died in November.

They analyzed marketing data from the U.S. Food and Drug Administration, Medicare, other federal and state agencies, private companies and medical research. The report covers 1997, when the FDA eased rules for TV ads, through 2016. Although some types of spending waxed and waned during those years, Woloshin said the upward trend is concerning and suggests consumers need to be increasingly skeptical about marketing claims.